Why Is Wholeleaf Raising A New Funding Round?
Pain therapeutics startup Wholeleaf is in advanced discussions to raise ₹7.5 crore in fresh funding as it looks to strengthen its position in India’s growing chronic pain management market.
According to sources familiar with the development, the Gurugram-based company is in talks with institutional investors IPV and Benzai 10 Capital for the upcoming investment round.
The fundraising comes at a crucial stage for the startup as it seeks to scale operations, deepen retail penetration, and expand awareness of its medically focused natural pain management solutions.
The company has emerged as one of the early players in India’s cannabinoid-based pain therapeutics segment, catering to consumers seeking alternative long-term solutions for chronic pain and related health conditions.
Who Has Invested In Wholeleaf So Far?
Wholeleaf has attracted interest from both institutional and prominent angel investors over the past few years.
Earlier this year, the startup secured ₹1.5 crore in funding from investors featured on Shark Tank India, including Aman Gupta, Kanika Tekriwal, and Namita Thapar.
Prior to that, the company raised ₹3.5 crore from ah! Ventures and a group of angel investors.
With the proposed ₹7.5 crore round, Wholeleaf’s total funding raised would significantly increase, providing additional resources to support its next phase of growth.
The continued investor interest reflects growing confidence in India’s health and wellness sector, particularly in specialized therapeutic categories focused on chronic health conditions.
How Will The Startup Use The Fresh Capital?
Wholeleaf plans to deploy the proceeds across multiple growth initiatives aimed at expanding both its reach and product capabilities.
The company intends to accelerate its offline retail expansion, strengthen product development efforts, scale distribution networks, and enhance brand visibility across online and offline channels.
Management believes that wider distribution and stronger consumer awareness will play a critical role in driving adoption of specialized pain therapeutics products in India.
The funding will also support investments in building a stronger product infrastructure capable of supporting future scale and regulatory requirements.
What Does Wholeleaf Do?
Founded in 2021 by Shivraj Sharma, Wholeleaf operates in the medically oriented pain therapeutics segment and focuses on developing natural solutions for chronic and neuropathic pain management.
The company currently offers a portfolio of oral tinctures and topical formulations designed to address various conditions, including migraines, arthritis, fibromyalgia, menstrual pain, anxiety, and sleep-related disorders.
In addition to its existing product lineup, Wholeleaf is developing a broader pipeline targeting chronic neuropathic pain, an area where treatment options remain limited for many patients.
The startup positions itself as a science-led company, emphasizing physician-guided product development and evidence-based validation processes.
How Large Is Wholeleaf’s Market Presence?
Wholeleaf claims to have built a retail presence across nearly 2,000 outlets, primarily concentrated in the Delhi-NCR region.
The company now plans an aggressive expansion strategy aimed at increasing its footprint to between 5,000 and 7,000 retail outlets over the coming year.
Its target markets include major metropolitan and tier-I cities such as Bengaluru, Mumbai, Hyderabad, Kolkata, Ahmedabad, Goa, and Chennai.
The expansion is expected to help the company tap into rising consumer demand for wellness-focused and non-invasive pain management solutions.
What Is Driving The Company’s Growth?
According to founder and CEO Shivraj Sharma, the company is balancing rapid growth with the need to build sustainable infrastructure and regulatory credibility.
Wholeleaf currently reports an annual recurring revenue (ARR) of approximately ₹18 crore and claims strong category penetration within the pain therapeutics segment.
The company follows a structured product development framework, with each formulation undergoing multiple validation stages, including safety testing, pilot studies, and third-party assessments conducted by government-certified laboratories.
As awareness around chronic pain management continues to grow, Wholeleaf is positioning itself to capitalize on increasing demand for scientifically validated and accessible therapeutic solutions.
